



## **ASX ANNOUNCEMENT**

12 June 2025

# **TRIALKEY DEEPENS GLOBAL AI COLLABORATIONS WITH CARDIALYSIS AND EVESTIA CLINICAL**

Opyl Limited (**ASX: OPL**) announces two strategic collaborations for its AI-enabled clinical trial design platform, TrialKey.ai, signing agreements with Netherlands-based Cardialysis and UK-based Evestia Clinical Limited. These partnerships mark an important step in TrialKey's mission to expand its global dataset, deepen therapeutic insights, and refine its AI engine through real-world clinical collaboration.

- Opyl (ASX: OPL) secures two new collaborations with Cardialysis (cardiovascular) and Evestia Clinical (oncology & rare disease), integrating its AI trial-design platform TrialKey.ai into upcoming studies.
- Partnerships enlarge TrialKey's global dataset and modelling power, sharpening protocol feasibility, endpoint optimisation and predicted success rate.
- Deals accelerate TrialKey's commercial rollout, laying the groundwork for recurring revenue as customers embed the platform in routine clinical-trial workflows.

### **Cardialysis – Advancing Cardiovascular AI Insights**

Cardialysis, a globally recognised full-service contract research organisation (CRO) dedicated to cardiovascular clinical trials, has completed more than 400 trials across 1,400 investigative sites, enrolling over 200,000 patients to date. The company currently manages approximately 40 active studies each year. Sponsors include Merck, AstraZeneca, Bayer, Novartis, Abbott, Boston Scientific, Medtronic and GSK. Cardialysis has engaged TrialKey to

Opyl Limited  
6 Middlemiss Street, Milsons Point  
NSW 2061  
ABN: 71 063 144 865  
[www.opyl.ai](http://www.opyl.ai)



enrich protocol design for its next-phase study. The TrialKey platform will be used to simulate outcomes, optimise endpoints, and align inclusion/exclusion criteria to regulatory standards and real-world recruitment feasibility.

By integrating TrialKey into its protocol development process, Cardialysis aims to enhance its precision medicine offerings and boost success probabilities through advanced AI modelling and real-world trial analytics. TrialKey's deep benchmarking capabilities and predictive analytics will be tested by Cardialysis for fine-tuning critical trial parameters in the cardiovascular domain.

### **Evestia Clinical – AI Partnership for Rare Disease and Oncology Trials**

Evestia Clinical Limited, a UK-based CRO specialising in complex therapeutic areas such as oncology, rare diseases and immunology, brings more than 25 years of global trial experience. Across its history (including operations as EMAS Pharma) Evestia has delivered over 480 clinical studies worldwide — comprising more than 300 oncology trials, 120 rare-disease programmes and 60 CNS studies from Phase I through Phase IV. Backed by UK healthcare investor Kester Capital since December 2024, Evestia manages an expanding portfolio of complex, high-stakes studies that will now leverage TrialKey's AI capabilities.

This engagement centres on a shared data and model-training initiative, wherein TrialKey will support feasibility optimisation across a pipeline of upcoming Evestia studies. The collaboration will yield insights to fine-tune the platform's handling of niche and underserved therapeutic areas, while delivering tangible value to Evestia's design teams through AI-guided design recommendations and performance modelling. Evestia's access to TrialKey will inform their planning decisions, while TrialKey gains exposure to emerging, high-complexity trial formats—expanding its AI capabilities and clinical intelligence in frontier indications.

For a summary of the key terms of each agreement please see Schedule 1.

Opyl Limited  
6 Middlemiss Street, Milsons Point  
NSW 2061  
ABN: 71 063 144 865  
[www.opyl.ai](http://www.opyl.ai)



## **Executive Commentary**

Opyl Executive Chair, Saurabh Jain, said:

*" TrialKey is not just a product—it's a learning system. These partnerships with Cardialysis and Evestia prove its value in the field today and propel us toward sustainable growth.*

- *Third-party validation – a high-throughput cardiology CRO (Cardialysis) and a long-standing oncology/rare-disease CRO (Evestia) are embedding TrialKey into live studies, demonstrating immediate market utility.*

- *Dataset expansion – Cardialysis contributes vast cardiovascular data, while Evestia adds rare-disease and oncology complexity, together sharpening TrialKey's AI models and predictive accuracy.*

- *Route to recurring revenue – as these partners move from pilot to routine use, Opyl will secure repeat licence fees and compelling case-study proof points that can accelerate broader adoption.*

We're laying the foundation for a smarter, more efficient clinical-trial ecosystem."

**This announcement has been authorised for release by the Board of Opyl Ltd.**

**-ENDS-**

## **For further information, please contact:**

Saurabh Jain  
Executive Chair  
Email: saurabh@trialkey.ai

## **About Opyl Limited (ASX: OPL)**

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.

Opyl Limited  
6 Middlemiss Street, Milsons Point  
NSW 2061  
ABN: 71 063 144 865  
[www.opyl.ai](http://www.opyl.ai)



## **Schedule 1 – Additional Information – Evestia and Cardialysis Agreements**

In relation to the agreements with Evestia Clinical Limited and Cardialysis B.V., the Company provides the following additional information:

1. The TrialKey platform provides both parties with detailed, AI-driven clinical trial design and optimisation reports.
  - a. Evestia projects start from AUD \$5,000, payable only upon successful engagement of a qualifying study.
  - b. Cardialysis projects start from AUD \$20,000 per trial, payable only if Cardialysis secures the client business.
2. There are no material conditions precedent that need to be satisfied before either party may adopt or use the TrialKey platform.
3. There is no minimum commitment or guaranteed volume of reports to be commissioned under either agreement.
4. There is no other material information relevant to assessing the impact of these agreements on the price or value of the Company's securities.
5. The Evestia agreement has a fixed term of three (3) years and may be terminated by either party for insolvency or unremedied material breach.
6. The Cardialysis agreement continues until a mutually agreed expiration date (with 30 days' notice) and may be terminated for insolvency or unremedied breach

Opyl Limited  
6 Middlemiss Street, Milsons Point  
NSW 2061  
ABN: 71 063 144 865  
[www.opyl.ai](http://www.opyl.ai)